G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Cause of death in patients with lower-risk myelodysplastic syndrome.
Farshid Dayyani,Anthony P. Conley,Sara S. Strom,William Stevenson,Jorge E. Cortes,Gautam Borthakur,Stefan Faderl,Susan O'Brien,Sherry Pierce,Hagop M. Kantarjian,Guillermo Garcia-Manero +10 more
TL;DR: The authors have recently shown that a majority of patients with myelodysplastic syndrome classified by the International Prognostic Scoring System as lower risk die without transformation to acute myelogenous leukemia (AML).
Journal ArticleDOI
Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis
Alfonso Quintás-Cardama,Hagop M. Kantarjian,Taghi Manshouri,Deborah A. Thomas,Jorge E. Cortes,Farhad Ravandi,Guillermo Garcia-Manero,Alessandra Ferrajoli,Carlos E. Bueso-Ramos,Srdan Verstovsek +9 more
TL;DR: The combination of lenalidomide and prednisone induces durable clinical, molecular, and pathologic responses in patients with myelofibrosis.
Journal ArticleDOI
Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia
TL;DR: The most recent results reported with HDACIs in clinical trials conducted in patients with MDS and other myeloid malignancies appear to be synergistic in vitro and improve response rates in vivo when combined with other agents, such as hypomethylating agents.
Journal ArticleDOI
Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
TL;DR: The myelodysplastic syndromes are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML).
Journal ArticleDOI
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults
Michael R. Savona,Luca Malcovati,Rami S. Komrokji,Ramon V. Tiu,Tariq I. Mughal,Attilio Orazi,Jean-Jacques Kiladjian,Eric Padron,Eric Solary,Raoul Tibes,Raphael Itzykson,Mario Cazzola,Ruben A. Mesa,Jaroslaw P. Maciejewski,Pierre Fenaux,Guillermo Garcia-Manero,Aaron T. Gerds,Guillermo Sanz,Charlotte M. Niemeyer,Francisco Cervantes,Ulrich Germing,Nicholas C.P. Cross,Alan F. List +22 more
TL;DR: This work proposes response assessment guidelines to harmonize future clinical trials with the principal objective of establishing suitable treatment algorithms for MDS/MPN.